# KEYNOTE-361 (NCT02853305)

> Study of Pembrolizumab With or Without Platinum-based Combination Chemotherapy Versus Chemotherapy Alone in Urothelial Carcinoma (MK-3475-361/KEYNOTE-361)

No report yet. It can be ordered.

- Drugs tested: pembrolizumab
- Indication: advanced or metastatic urothelial carcinoma

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT02853305
- Phase: PHASE3
- Status: COMPLETED
- Sponsor: Merck Sharp & Dohme LLC
- Conditions: Urothelial Carcinoma Associated 1 RNA, Human
- Interventions: Pembrolizumab; Cisplatin; Carboplatin; Gemcitabine
- Enrollment: 1010
- Primary outcome: Pembro Combo vs Chemo: Progression-free Survival (PFS) Using Response Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR)
- Primary outcome: Pembro Combo vs Chemo: Overall Survival (OS)
- Primary outcome: Pembro vs Chemo: OS in Participants With Programmed Cell Death Ligand 1 (PD-L1) Combined Positive Score (CPS) ≥10%
- Primary outcome: Pembro vs Chemo: OS

## Indexed commentary on KEYNOTE-361 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 3

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=keynote-361-nct02853305